Optical coherence tomography evaluation of drug-eluting stents: A systematic review

Catheterization and Cardiovascular Interventions

Volumn 81, Issue 3, 2013, Pages 481-487

  Papayannis, Aristotelis C ^a   Cipher, Daisha ^b   Banerjee, Subhash ^a   Brilakis, Emmanouil S ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

Author keywords

coronary artery disease; optical coherence tomography; restenosis

Indexed keywords

EVEROLIMUS; PACLITAXEL; ZOTAROLIMUS;

CARDIAC IMAGING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CORONARY ARTERY DISEASE; CORONARY STENT; DIAGNOSTIC IMAGING; DRUG ELUTING STENT; EQUIPMENT DESIGN; FOLLOW UP; HUMAN; MEDICAL DEVICE COMPLICATION; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; REVIEW; SYSTEMATIC REVIEW;

CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL REVASCULARIZATION; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84874118551     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24327     Document Type: Review

References (61)

1. Garg S, Serruys PW,. Coronary stents: Current status. J Am Coll Cardiol 2010; 56: S1-42.
2. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
3. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD,. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004; 109: 701-705.
4. Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R,. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol 2011; 57: 390-398.
5. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S,. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115: 2426-2434.
6. Murata A, Wallace-Bradley D, Tellez A, Alviar C, Aboodi M, Sheehy A, Coleman L, Perkins L, Nakazawa G, Mintz G, et al. Accuracy of optical coherence tomography in the evaluation of neointimal coverage after stent implantation. JACC Cardiovasc Imaging 2010; 3: 76-84.
7. Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishida T, Takemoto Y, Onoue K, Somekawa S, Takeda Y, et al. Long-term follow-up of neointimal coverage of sirolimus-eluting stents-Evaluation with optical coherence tomography. Circ J 2009; 73: 2300-2307.
8. Tanaka N, Terashima M, Rathore S, Itoh T, Habara M, Nasu K, Kimura M, Kinoshita Y, Ehara M, Tsuchikane E, et al. Different patterns of vascular response between patients with or without diabetes mellitus after drug-eluting stent implantation: Optical coherence tomographic analysis. JACC Cardiovasc Interv 2010; 3: 1074-1079.
9. Kim JS, Fan C, Choi D, Jang IK, Lee JM, Kim TH, Park SM, Paik SI, Ko YG, Hong MK, et al. Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study. Int J Cardiol 2011; 146: 341-346.
10. Chen BX, Ma FY, Luo W, Ruan JH, Xie WL, Zhao XZ, Sun SH, Guo XM, Wang F, Tian T, et al. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart 2008; 94: 566-570.
11. Ozaki Y, Okumura M, Ismail TF, Naruse H, Hattori K, Kan S, Ishikawa M, Kawai T, Takagi Y, Ishii J, et al. The fate of incomplete stent apposition with drug-eluting stents: An optical coherence tomography-based natural history study. Eur Heart J 2010; 31: 1470-1476.
12. Guagliumi G, Costa MA, Sirbu V, Musumeci G, Bezerra HG, Suzuki N, Matiashvili A, Lortkipanidze N, Mihalcsik L, Trivisonno A, et al. Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: Optical coherence tomography substudy of the harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) trial. Circulation 2011; 123: 274-281.
13. Inoue T, Shite J, Yoon J, Shinke T, Otake H, Sawada T, Kawamori H, Katoh H, Miyoshi N, Yoshino N, et al. Optical coherence evaluation of everolimus-eluting stents 8 months after implantation. Heart 2011; 97: 1379-1384.
14. Kim TH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK,. Long-term (>/=2 years) follow-up optical coherence tomographic study after sirolimus- and paclitaxel-eluting stent implantation: Comparison to 9-month follow-up results. Int J Cardiovasc Imaging 2011; 27: 875-881.
15. Takano M, Yamamoto M, Mizuno M, Murakami D, Inami T, Kimata N, Murai K, Kobayashi N, Okamatsu K, Ohba T, et al. Late vascular responses from 2 to 4 years after implantation of sirolimus-eluting stents: Serial observations by intracoronary optical coherence tomography. Circ Cardiovasc Interv 2010; 3: 476-483.
16. Xie Y, He SH, Gu X, Xu RX, Masamichi T, Kyoichi M,. [Evaluation of neointimal coverage and thrombosis at 3 months and 2 years post sirolimus-eluting stent implantation by optical coherence tomography]. Zhonghua Xin Xue Guan Bing Za Zhi 2010; 38: 116-120.
17. Moore P, Barlis P, Spiro J, Ghimire G, Roughton M, Di Mario C, Wallis W, Ilsley C, Mitchell A, Mason M, et al. A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents. JACC Cardiovasc Interv 2009; 2: 437-444.
18. Xie Y, Takano M, Murakami D, Yamamoto M, Okamatsu K, Inami S, Seimiya K, Ohba T, Seino Y, Mizuno K,. Comparison of neointimal coverage by optical coherence tomography of a sirolimus-eluting stent versus a bare-metal stent three months after implantation. Am J Cardiol 2008; 102: 27-31.
19. Takano M, Inami S, Jang IK, Yamamoto M, Murakami D, Seimiya K, Ohba T, Mizuno K,. Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol 2007; 99: 1033-1038.
20. Guagliumi G, Musumeci G, Sirbu V, Bezerra HG, Suzuki N, Fiocca L, Matiashvili A, Lortkipanidze N, Trivisonno A, Valsecchi O, et al. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. JACC Cardiovasc Interv 2010; 3: 531-539.
21. Miyoshi N, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Kawamori H, Kato H, Yoshino N, et al. Comparison by optical coherence tomography of paclitaxel-eluting stents with sirolimus-eluting stents implanted in one coronary artery in one procedure.-6-month follow-up-. Circ J 2010; 74: 903-908.
22. Murakami D, Takano M, Yamamoto M, Inami S, Ohba T, Seino Y, Mizuno K,. Advanced neointimal growth is not associated with a low risk of in-stent thrombus. Optical coherence tomographic findings after first-generation drug-eluting stent implantation. Circ J 2009; 73: 1627-1634.
23. Katoh H, Shite J, Shinke T, Matsumoto D, Tanino Y, Ogasawara D, Sawada T, Miyoshi N, Kawamori H, Yoshino N, et al. Delayed neointimalization on sirolimus-eluting stents: 6-month and 12-month follow-up by optical coherence tomography. Circ J 2009; 73: 1033-1037.
24. Yao ZH, Matsubara T, Inada T, Suzuki Y, Suzuki T,. Neointimal coverage of sirolimus-eluting stents 6 months and 12 months after implantation: Evaluation by optical coherence tomography. Chin Med J (Engl) 2008; 121: 503-507.
25. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M,. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: Evaluated by optical coherence tomography. Eur Heart J 2007; 28: 961-967.
26. Choi HH, Kim JS, Yoon DH, Hong KS, Kim TH, Kim BK, Ko YG, Choi D, Jang Y, Hong MK,. Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: Comparison with sirolimus-eluting stent using optical coherence tomography. Int J Cardiovasc Imaging (in press).
27. Kim JS, Kim TH, Fan C, Lee JM, Kim W, Ko YG, Choi D, Hong MK, Jang Y,. Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxel-eluting stents using optical coherence tomography at 9 months after implantation. Circ J 2010; 74: 320-326.
28. Barlis P, Regar E, Serruys PW, Dimopoulos K, van der Giessen WJ, van Geuns RJ, Ferrante G, Wandel S, Windecker S, van Es GA, et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: A LEADERS trial sub-study. Eur Heart J 2010; 31: 165-176.
29. Fan C, Kim JS, Lee JM, Kim TH, Park SM, Wi J, Paik SI, Ko YG, Choi D, Hong MK, et al. Different vascular healing patterns with various drug-eluting stents in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Optical coherence tomographic findings. Am J Cardiol 2010; 105: 972-976.
30. Liu Y, Imanishi T, Kubo T, Tanaka A, Kitabata H, Tanimoto T, Ino Y, Ikejima H, Tsujioka H, Komukai K, et al. Assessment by optical coherence tomography of stent struts across side branch. -Comparison of bare-metal stents and drug-elution stents. Circ J 2010; 75: 106-112.
31. Kim JS, Jang IK, Kim TH, Takano M, Kume T, Hur NW, Ko YG, Choi D, Hong MK, Jang Y,. Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: Comparison with sirolimus-eluting stents. Heart 2009; 95: 1907-1912.
32. Tian F, Chen YD, Sun ZJ, Chen L, Yuan F, Song XT, Lu SZ,. Evaluation of neointimal coverage of overlapping sirolimus-eluting stents by optical coherence tomography. Chin Med J (Engl) 2009; 122: 670-674.
33. Guagliumi G, Sirbu V, Musumeci G, Bezerra HG, Aprile A, Kyono H, Fiocca L, Matiashvili A, Lortkipanidze N, Vassileva A, et al. Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical coherence tomography drug-eluting stent investigation (OCTDESI). Circ Cardiovasc Interv 2010; 3: 367-375.
34. Davlouros PA, Nikokiris G, Karantalis V, Mavronasiou E, Xanthopoulou I, Damelou A, Tsigkas G, Alexopoulos D,. Neointimal coverage and stent strut apposition six months after implantation of a paclitaxel eluting stent in acute coronary syndromes: An optical coherence tomography study. Int J Cardiol 2011; 151: 155-159.
35. Motreff P, Souteyrand G, Levesque S, Ouchchane L, Dauphin C, Sarry L, Cassagnes J, Lusson JR,. Comparative analysis of neointimal coverage with paclitaxel and zotarolimus drug-eluting stents, using optical coherence tomography 6 months after implantation. Arch Cardiovasc Dis 2009; 102: 617-624.
36. Fujii K, Kawasaki D, Oka K, Akahori H, Fukunaga M, Sawada H, Masutani M, Lee-Kawabata M, Tsujino T, Ohyanagi M, et al. Endothelium-dependent coronary vasomotor response and neointimal coverage of zotarolimus-eluting stents 3 months after implantation. Heart 2011; 97: 977-982.
37. Kim JS, Jang IK, Fan C, Kim TH, Park SM, Choi EY, Lee SH, Ko YG, Choi D, Hong MK, et al. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: The ENDEAVOR OCT trial. JACC Cardiovasc Interv 2009; 2: 1240-1247.
38. Souteyrand G, Levesque S, Ouchchane L, Sarry L, Eschalier R, Lusson JR, Motreff P,. Spatial distribution of neo-intimal hyperplasia 6 months after zotarolimus-eluting stent implantation, analysed by optical coherence tomography. Arch Cardiovasc Dis 2011; 104: 147-154.
39. Guagliumi G, Sirbu V, Bezerra H, Biondi-Zoccai G, Fiocca L, Musumeci G, Matiashvili A, Lortkipanidze N, Tahara S, Valsecchi O, et al. Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: The OCTAMI (optical coherence tomography in acute myocardial infarction) study. JACC Cardiovasc Interv 2010; 3: 680-687.
40. Regar E, Schaar J, van der Giessen W, van der Steen AF, Serruys PW,. Real-time, in-vivo optical coherence tomography of human coronary artery using a dedicated imaging wire. Am J Cardiol 2002; 90 (suppl 6A):129H.
41. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia G, Natali A, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 233-246.
42. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: A statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 7-17.
43. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R,. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441.
44. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R,. Drug-eluting stent and coronary thrombosis: Biological mechanisms and clinical implications. Circulation 2007; 115: 1051-1058.
45. Pilgrim T, Windecker S,. Drug-eluting stent thrombosis. Minerva Cardioangiol 2009; 57: 611-620.
46. Nakazawa G, Finn AV, Ladich E, Ribichini F, Coleman L, Kolodgie FD, Virmani R,. Drug-eluting stent safety: Findings from preclinical studies. Expert Rev Cardiovasc Ther 2008; 6: 1379-1391.
47. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R,. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
48. Tanigawa J, Barlis P, Dimopoulos K, Dalby M, Moore P, Di Mario C,. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. Int J Cardiol 2009; 134: 180-188.
49. Degertekin M, Regar E, Tanabe K, Lemos P, Lee CH, Smits P, de Feyter P, Bruining N, Sousa E, Abizaid A, et al. Evaluation of coronary remodeling after sirolimus-eluting stent implantation by serial three-dimensional intravascular ultrasound. Am J Cardiol 2003; 91: 1046-1050.
50. Mintz GS, Shah VM, Weissman NJ,. Regional remodeling as the cause of late stent malapposition. Circulation 2003; 107: 2660-2663.
51. van der Hoeven BL, Liem SS, Dijkstra J, Bergheanu SC, Putter H, Antoni ML, Atsma DE, Bootsma M, Zeppenfeld K, Jukema JW, et al. Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: Acute and 9-month intravascular ultrasound results of the MISSION! intervention study. JACC Cardiovasc Interv 2008; 1: 192-201.
52. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger M, Seiler C, et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009; 120: 391-399.
53. Garcia-Touchard A, Burke SE, Toner JL, Cromack K, Schwartz RS,. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J 2006; 27: 988-993.
54. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: A randomized controlled trial. J Am Coll Cardiol 2006; 48: 2440-2447.
55. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R,. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007; 100: 36M-44M.
56. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52: 333-342.
57. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-1674.
58. Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (clinical evaluation of the XIENCE V everolimus eluting coronary stent system) IV trial. J Am Coll Cardiol 2011; 58: 19-25.
59. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC,. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010; 375: 201-209.
60. Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, McFadden E,. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: A randomized open label trial). J Am Coll Cardiol 2011; 58: 11-18.
61. Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari DE,. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease) trial. JACC Cardiovasc Interv 2010; 3: 1043-1050.